Product Theatre

PDM-08 - SEGLENTIS® (celecoxib 56 mg and tramadol hydrochloride 44 mg) C-IV: The first and only multimodal co-crystal for the treatment of acute pain in appropriate patients

Thursday, September 8, 2022

3:40 PM – 4:30 PM

Location: L3/Brera Ballroom

Sponsored By

Symposium Speaker(s)

Charles E. Argoff, MD

Pain Medicine Specialist
Albany Medical Center
Albany Medical Center
Albany, New York
EV

Eugene R. Viscusi, MD

Professor of Anesthesiology, Chief of Pain Medicine, and Director, Acute Pain Management
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania

"This product theater is sponsored by Kowa Pharmaceuticals America, Inc., and is designed to highlight key background about acute pain management as well as SEGLENTIS clinical information, such as Important Safety Information, including Boxed Warning, dosing and administration, safety, and efficacy, from the pivotal Phase III clinical trial.

Under FDA laws, regulations, and guidance, speaker programs and any other marketing activities that promote our products must present information consistent with SEGLENTIS approved product labeling. This is a promotional program, and no CME credits are offered.

Sponsored by Kowa Pharmaceuticals America, Inc.